Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYGCSV)

• Drug Name: N1-(naphthalen-1-yl)ethane-1,2-diamine Drug Info
• Synonyms: N-(1-Naphthyl)ethylenediamine; 551-09-7; N1-(naphthalen-1-yl)ethane-1,2-diamine; N-(1-naphthyl)ethane-1,2-diamine; 1,2-Ethanediamine, N-1-naphthalenyl-; UNII-02X37521XE; CHEMBL1214195; CHEBI:53510; NULAJYZBOLVQPQ-UHFFFAOYSA-N; N-naphthalen-1-ylethane-1,2-diamine; 02X37521XE; 1,2-Ethanediamine, N1-1-naphthalenyl-; N-(naphthalen-1-yl)ethane-1,2-diamine; NCGC00163705-03; N-1-naphthylethylenediamine; Oprea1_329986; EINECS 208-992-9; (2-aminoethyl)naphthylamine; N-1-naphthylethylene diamine; SCHEMBL233681

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 15107
  ChEBI ID: CHEBI:53510
  CAS Number: CAS 551-09-7
  TTD Drug ID: DMYGCSV

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[3]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[4]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[1]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[6]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[3]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[10]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[6]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[9]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[11]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[1]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[1]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[6]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[12]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[4]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[13]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[14]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[15]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[3]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[16]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[17]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[18]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[14]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[6]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[7]
INDISULAM	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[19]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[20]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[21]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[23]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[6]

Drug(s) Affected By Poly(rC)-binding protein 3 (PCBP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[26]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[29]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[30]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[31]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[32]

Drug(s) Affected By Fibronectin type III domain-containing protein 8 (FNDC8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[33]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[1]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[1]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[1]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[1]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Fibronectin type III domain-containing protein 8 (FNDC8)	OT6I682D	FNDC8_HUMAN	Drug Response	[2]
Poly(rC)-binding protein 3 (PCBP3)	OT6EX9N6	PCBP3_HUMAN	Drug Response	[2]

References

• [1] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [2] Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
• [3] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [4] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [5] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [6] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [7] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [8] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [9] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [10] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [11] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [12] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [13] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [14] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [15] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [16] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [18] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [19] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [20] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [21] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [22] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [23] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
• [24] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [27] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [28] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [29] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [30] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [31] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [32] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [33] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.